ReviewPharmacological research
alpha-Synuclein: a therapeutic target for Parkinson's disease?
Review in Pharmacological research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 40 citations in OpenAlex.
- Microglia-derived extracellular vesicles attenuate acute a-synuclein induced astrocyte inflammation.bioRxiv : the preprint server for biology · 2026Article
- The effect of SARS-CoV-2 on the development of Parkinson's disease: the role of α-synuclein.Human cell · 2024Review
- Current Therapies in Clinical Trials of Parkinson's Disease: A 2021 Update.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Tetramethylpyrazine Analogue T-006 Promotes the Clearance of Alpha-synuclein by Enhancing Proteasome Activity in Parkinson's Disease Models.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2019Article
- Protective effects of salidroside in the MPTP/MPP(+)-induced model of Parkinson's disease through ROS-NO-related mitochondrion pathway.Molecular neurobiology · 2015Article
- Interleukin-22 protects rat PC12 pheochromocytoma cells from serum deprivation-induced cell death.Molecular and cellular biochemistry · 2012Article
- Rafts, Nanoparticles and Neural Disease.Nanomaterials (Basel, Switzerland) · 2012Review
- Misfolded α-synuclein and Toll-like receptors: therapeutic targets for Parkinson's disease.Parkinsonism & related disorders · 2012Review
- Parkinson's disease.Sub-cellular biochemistry · 2012Review
- Pharmacological therapy in Parkinson's disease: focus on neuroprotection.CNS neuroscience & therapeutics · 2011Review
- Parkinson's disease, cortical dysfunction, and alpha-synuclein.Movement disorders : official journal of the Movement Disorder Society · 2011Article
- Specificity and kinetics of alpha-synuclein binding to model membranes determined with fluorescent excited state intramolecular proton transfer (ESIPT) probe.The Journal of biological chemistry · 2011Article
- Future directions for immune modulation in neurodegenerative disorders: focus on Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2010Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Parkinson's disease is a progressive age-related neurodegenerative disease with invariant loss of substantia nigra dopamine neurons and striatal projections. This disorder is well known for the associated motoric symptoms including resting tremor and the inability to initiate movement. However, it is now apparent that Parkinson's disease is a multisystem disorder with patients exhibiting symptoms derived from peripheral nervous system and extra-nigral dysfunctions in addition to the prototypical nigrostriatal damage. Although the etiology for sporadic Parkinson's disease is unknown, information gleaned from both familial forms of the disease and animal models places misfolded alpha-synuclein at the forefront. The disease is currently without a cure and most therapies target the motoric symptoms relying on increasing dopamine tone. In this review, the role of alpha-synuclein in disease pathogenesis and as a potential therapeutic target focusing on toxic conformers of this protein is considered. The addition of protofibrillar/oligomer-directed neurotherapeutics to the existing armamentarium may extend the symptom-free stage of Parkinson's disease as well as alleviate pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.